Abstract
The pharmacokinetic properties of absorption, distribution, metabolism and excretion (ADME) play a crucial role in drug discovery and development, since many drug candidates fail due to an inappropriate pharmacokinetic profile. Cytochrome P450 (CYP) enzymes are predominantly involved in Phase 1 metabolism of xenobiotics. Thus, it is important to better understand and prognosticate substrate binding and inhibition of CYP450.The goal of this study was to obtain QSAR (Quantitative Structure-Activity Relationship) models to identify substrates and inhibitors of CYP3A4. The data sets were collected and curated from online available databases and literature. Several QSAR models were obtained and validated according to the recommendations of the Organization for Economic Co-operation Development (OECD). The combination of different descriptors and machine learning methods led to robust and predictive QSAR models with high coverage. The interpretation of developed models was performed using the predicted probability maps (PPM). These maps help to encode major structural fragments to classify compounds as inhibitors or not inhibitors of CYP3A4. In conclusion, the obtained models can reliably identify substrates and non-substrates, and inhibitors and non-inhibitors of CYP3A4, which is very important in the early stages of the development of new drugs.
Highlights
Many drug candidates fail during the drug development process in clinical trials due to an inappropriate pharmacokinetic profile
ADME/Tox properties are the major contributors to the failures of new drugs in the development pipeline and often the underlying biological mechanism of toxicity is related to metabolism
The combination of different descriptors and machine learning (ML) methods led to robust and predictive QSAR models for substrates of CYP3A4, with correct classification rate (CCR) values ranging between 0.65-0.83 and coverage of 0.69-0.89
Summary
Many drug candidates fail during the drug development process in clinical trials due to an inappropriate pharmacokinetic profile. For this reason, the study of the pharmacokinetic properties absorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) of a drug candidate is important to reduce time and. ADME/Tox properties are the major contributors to the failures of new drugs in the development pipeline and often the underlying biological mechanism of toxicity is related to metabolism. The main goal of this study was to develop robust and predictive models that can be used to classify compound as inhibitor/non-inhibitor or substrate/non-substrate of CYP3A4 for identifying and discarding drug candidates with potential metabolism issues
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
